🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hosting the one and only Dr. Ian Tannock at The Late Night Oncology Show 🎙️ is a landmark in our career and podcast! Stay tuned for more!

🔥🔥🔥What a wonderful final foy our Program in Clinical Effectiveness!!!! Harvard T.H. Chan School of Public Health Harvard University

Very proud to work with Carolina Reduzzi Eleonora Nicolò & International Society of Liquid Biopsy young group in this review on 20years of CTCs discovery #liquidbiopsy 🩺 Clinical significance 📊 Multi-analyte analysis ⏩ Future perspectives & clinical trials 💊 👇 sciencedirect.com/science/articl…

Bye Barcelona, it’s a wrap! So intense days of new knowledge and global friendship in #ESMO24 🤩

Impact of the Early Phase of the Coronavirus Disease 2019 (#COVID19) Pandemic on the Quality of Care for Colorectal and Anal Cancer at Comprehensive Cancer Centres on Two Continents: brnw.ch/21wNsMG Erick Saldanha, MD #crcsm #ancsm

Survey Participation Request on Behalf of International Society of Liquid Biopsy & OncoAlert Oncologist Attitudes and Practices on Liquid Biopsy 👉 buff.ly/4kgngY6 This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your

This is a nice effort from a Brazilian 🇧🇷 large team led by our good friend gilberto lopes Sylvester Comprehensive Cancer Center —the application can one day happen beyond lung cancer and perhaps decrease the intensity of CTs The Oncologist IASLC

Happy to share our work led by the rising star Luís Felipe Leite, highlighting the role of ctDNA kinetics in predicting treatment outcomes for patients with NSCLC. Check it out! 💥 International Society of Liquid Biopsy Carolina Reduzzi

Our paper describing the frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients is out at The Oncologist! Mutation rate 2.8% (mostly never smokers). rwOS-25.9 mo. Congratulatios to Erick Saldanha, MD, Andres F. Cardona and all CLICaP! acrobat.adobe.com/id/urn:aaid:sc…

Proud to share this amazing collaborative effort reporting the largest cohort to date on LATAM patients with ERBB2-mutant NSCLC. Thanks to this amazing team of authors!! Vladmir C. Cordeiro de Lima, MD, PhD Marcelo Corassa, MD. Gil-Santana Helano Freitas Aline Fares Andres F. Cardona Diego F. Chamorro

Frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients - Vladmir C. Cordeiro de Lima, MD, PhD Erick Saldanha, MD Andres F. Cardona oncodaily.com/science/vladmi… #OncoDaily #Oncology #Cancer #Health #Medicine #NSCLC #MedTwitter #MedEd #MedOnc #MedNews

Now you can find the link to complete our International Society of Liquid Biopsy survey in the OncoAlert newsletter! 📨 It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide! bit.ly/43JzN03 Carolina Reduzzi Christian Rolfo Umberto Malapelle Gil Morgan, MD

📌Happy to share our perspective on uveal melanoma management, just out in ESMO Open With this amazing team Maurício Ribeiro, MD Ian Hirsch 🔗 esmoopen.com/article/S2059-…

🔊Thrilled to share our paper, just out in Annals of Oncology ESMO - Eur. Oncology We assessed the role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade response for patients with solid tumours. Proud to be part of this effort alongside a brilliant group of

🚨New paper alert! Published in Annals of Oncology ESMO - Eur. Oncology -->Our systematic review & meta-analysis explores the role of "Circulating tumor DNA (ctDNA) clearance as a predictive biomarker for solid tumors treated with neoadjuvant immune-checkpoint inhibitors."🧬✨ Key takeaways:

🚨📣🩸participate on the first global survey on attitudes, practices & barriers to #LiquidBiopsy use among clinical oncologists! 🌍 International Society of Liquid Biopsy It takes just 10 minutes⏰ and it will help to shape the future of cancer care! 👉 docs.google.com/forms/d/e/1FAI…

Happy to share our latest work published in Annals of Oncology: 🚫 Lack of ctDNA clearance during neoadj IO may identify patients unlikely to achieve pCR. ⚠️ ctDNA clearance has limited confirmatory power due to low specificity and high heterogeneity. Thanks to all coauthors!

Our new manuscript is now available in open access👇🏻 Check it out below and let us know your thoughts! Erick Saldanha, MD The ASCO Post BMJ Oncology

Our review on key advancements in #liquidbiopsy in 2024 is finally out! This work was made possible thanks to the incredible team effort of the International Society of Liquid Biopsy Young Committee. 📰Check it out! ➡️ sciencedirect.com/science/articl…

International Society of Liquid Biopsy Carolina Reduzzi Mohamed A Gouda Cristofanilli CTC Laboratory Eleonora Nicolò Letizia Pontolillo @shurbisinghal @diegodemiguelperez Erick Saldanha, MD Pasquale Pisapia Konstantinos Venetis Ana Ortega Franco Dr. Nadia Ghazali Christian Rolfo Umberto Malapelle M JOSE SERRANO Lab (LB&Cancer Interception group) David Gandara ELO